nodes	percent_of_prediction	percent_of_DWPC	metapath
Neostigmine—Respiratory arrest—Vandetanib—thyroid cancer	0.0653	0.0653	CcSEcCtD
Neostigmine—Cardiac arrest—Vandetanib—thyroid cancer	0.0198	0.0198	CcSEcCtD
Neostigmine—Bronchospasm—Vandetanib—thyroid cancer	0.0177	0.0177	CcSEcCtD
Neostigmine—Pollakiuria—Vandetanib—thyroid cancer	0.0166	0.0166	CcSEcCtD
Neostigmine—Bradycardia—Vandetanib—thyroid cancer	0.0147	0.0147	CcSEcCtD
Neostigmine—Urinary tract disorder—Vandetanib—thyroid cancer	0.0142	0.0142	CcSEcCtD
Neostigmine—Urethral disorder—Vandetanib—thyroid cancer	0.0141	0.0141	CcSEcCtD
Neostigmine—Mediastinal disorder—Vandetanib—thyroid cancer	0.013	0.013	CcSEcCtD
Neostigmine—Arrhythmia—Vandetanib—thyroid cancer	0.0129	0.0129	CcSEcCtD
Neostigmine—Mental disorder—Vandetanib—thyroid cancer	0.0126	0.0126	CcSEcCtD
Neostigmine—Lacrimation—Epirubicin—thyroid cancer	0.0122	0.0122	CcSEcCtD
Neostigmine—Muscle spasms—Vandetanib—thyroid cancer	0.0121	0.0121	CcSEcCtD
Neostigmine—Lacrimation—Doxorubicin—thyroid cancer	0.0113	0.0113	CcSEcCtD
Neostigmine—Loss of consciousness—Vandetanib—thyroid cancer	0.011	0.011	CcSEcCtD
Neostigmine—Convulsion—Vandetanib—thyroid cancer	0.0109	0.0109	CcSEcCtD
Neostigmine—Arthralgia—Vandetanib—thyroid cancer	0.0107	0.0107	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.0106	0.0106	CcSEcCtD
Neostigmine—Dry mouth—Vandetanib—thyroid cancer	0.0104	0.0104	CcSEcCtD
Neostigmine—Paralysis—Epirubicin—thyroid cancer	0.0103	0.0103	CcSEcCtD
Neostigmine—Nervous system disorder—Vandetanib—thyroid cancer	0.01	0.01	CcSEcCtD
Neostigmine—Nystagmus—Epirubicin—thyroid cancer	0.01	0.01	CcSEcCtD
Neostigmine—Skin disorder—Vandetanib—thyroid cancer	0.00995	0.00995	CcSEcCtD
Neostigmine—Urinary tract disorder—Sorafenib—thyroid cancer	0.0096	0.0096	CcSEcCtD
Neostigmine—Connective tissue disorder—Sorafenib—thyroid cancer	0.00956	0.00956	CcSEcCtD
Neostigmine—Urethral disorder—Sorafenib—thyroid cancer	0.00953	0.00953	CcSEcCtD
Neostigmine—Paralysis—Doxorubicin—thyroid cancer	0.00953	0.00953	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00933	0.00933	CcSEcCtD
Neostigmine—Nystagmus—Doxorubicin—thyroid cancer	0.00927	0.00927	CcSEcCtD
Neostigmine—Insomnia—Vandetanib—thyroid cancer	0.00926	0.00926	CcSEcCtD
Neostigmine—Dyspnoea—Vandetanib—thyroid cancer	0.00913	0.00913	CcSEcCtD
Neostigmine—Flushing—Sorafenib—thyroid cancer	0.00903	0.00903	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00884	0.00884	CcSEcCtD
Neostigmine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00876	0.00876	CcSEcCtD
Neostigmine—Arrhythmia—Sorafenib—thyroid cancer	0.00869	0.00869	CcSEcCtD
Neostigmine—Mental disorder—Sorafenib—thyroid cancer	0.00852	0.00852	CcSEcCtD
Neostigmine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00838	0.00838	CcSEcCtD
Neostigmine—Cardiovascular disorder—Epirubicin—thyroid cancer	0.00815	0.00815	CcSEcCtD
Neostigmine—Muscle spasms—Sorafenib—thyroid cancer	0.00814	0.00814	CcSEcCtD
Neostigmine—Abdominal pain—Vandetanib—thyroid cancer	0.0081	0.0081	CcSEcCtD
Neostigmine—Lacrimation increased—Epirubicin—thyroid cancer	0.00777	0.00777	CcSEcCtD
Neostigmine—Syncope—Sorafenib—thyroid cancer	0.00759	0.00759	CcSEcCtD
Neostigmine—Dysarthria—Epirubicin—thyroid cancer	0.00757	0.00757	CcSEcCtD
Neostigmine—Cardiovascular disorder—Doxorubicin—thyroid cancer	0.00754	0.00754	CcSEcCtD
Neostigmine—Loss of consciousness—Sorafenib—thyroid cancer	0.00744	0.00744	CcSEcCtD
Neostigmine—Atrioventricular block—Epirubicin—thyroid cancer	0.00738	0.00738	CcSEcCtD
Neostigmine—Asthenia—Vandetanib—thyroid cancer	0.00735	0.00735	CcSEcCtD
Neostigmine—Pruritus—Vandetanib—thyroid cancer	0.00725	0.00725	CcSEcCtD
Neostigmine—Arthralgia—Sorafenib—thyroid cancer	0.00721	0.00721	CcSEcCtD
Neostigmine—Lacrimation increased—Doxorubicin—thyroid cancer	0.00719	0.00719	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00716	0.00716	CcSEcCtD
Neostigmine—Dry mouth—Sorafenib—thyroid cancer	0.00705	0.00705	CcSEcCtD
Neostigmine—Diarrhoea—Vandetanib—thyroid cancer	0.00701	0.00701	CcSEcCtD
Neostigmine—Dysarthria—Doxorubicin—thyroid cancer	0.007	0.007	CcSEcCtD
Neostigmine—Salivary hypersecretion—Epirubicin—thyroid cancer	0.00695	0.00695	CcSEcCtD
Neostigmine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00691	0.00691	CcSEcCtD
Neostigmine—Atrioventricular block—Doxorubicin—thyroid cancer	0.00683	0.00683	CcSEcCtD
Neostigmine—Shock—Sorafenib—thyroid cancer	0.0068	0.0068	CcSEcCtD
Neostigmine—Nervous system disorder—Sorafenib—thyroid cancer	0.00678	0.00678	CcSEcCtD
Neostigmine—Dizziness—Vandetanib—thyroid cancer	0.00677	0.00677	CcSEcCtD
Neostigmine—Skin disorder—Sorafenib—thyroid cancer	0.00671	0.00671	CcSEcCtD
Neostigmine—Coma—Epirubicin—thyroid cancer	0.00654	0.00654	CcSEcCtD
Neostigmine—Vomiting—Vandetanib—thyroid cancer	0.00651	0.00651	CcSEcCtD
Neostigmine—Rash—Vandetanib—thyroid cancer	0.00646	0.00646	CcSEcCtD
Neostigmine—Dermatitis—Vandetanib—thyroid cancer	0.00645	0.00645	CcSEcCtD
Neostigmine—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.00643	0.00643	CcSEcCtD
Neostigmine—Headache—Vandetanib—thyroid cancer	0.00642	0.00642	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00629	0.00629	CcSEcCtD
Neostigmine—Dyspnoea—Sorafenib—thyroid cancer	0.00616	0.00616	CcSEcCtD
Neostigmine—Nausea—Vandetanib—thyroid cancer	0.00608	0.00608	CcSEcCtD
Neostigmine—Coma—Doxorubicin—thyroid cancer	0.00605	0.00605	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00597	0.00597	CcSEcCtD
Neostigmine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00565	0.00565	CcSEcCtD
Neostigmine—Urticaria—Sorafenib—thyroid cancer	0.00549	0.00549	CcSEcCtD
Neostigmine—Abdominal pain—Sorafenib—thyroid cancer	0.00546	0.00546	CcSEcCtD
Neostigmine—Osteoarthritis—Epirubicin—thyroid cancer	0.0052	0.0052	CcSEcCtD
Neostigmine—Hypersensitivity—Sorafenib—thyroid cancer	0.00509	0.00509	CcSEcCtD
Neostigmine—Asthenia—Sorafenib—thyroid cancer	0.00496	0.00496	CcSEcCtD
Neostigmine—Cardiac arrest—Epirubicin—thyroid cancer	0.00494	0.00494	CcSEcCtD
Neostigmine—Pruritus—Sorafenib—thyroid cancer	0.00489	0.00489	CcSEcCtD
Neostigmine—Osteoarthritis—Doxorubicin—thyroid cancer	0.00481	0.00481	CcSEcCtD
Neostigmine—Diarrhoea—Sorafenib—thyroid cancer	0.00473	0.00473	CcSEcCtD
Neostigmine—Cardiac arrest—Doxorubicin—thyroid cancer	0.00457	0.00457	CcSEcCtD
Neostigmine—Dizziness—Sorafenib—thyroid cancer	0.00457	0.00457	CcSEcCtD
Neostigmine—Vomiting—Sorafenib—thyroid cancer	0.00439	0.00439	CcSEcCtD
Neostigmine—Rash—Sorafenib—thyroid cancer	0.00436	0.00436	CcSEcCtD
Neostigmine—Dermatitis—Sorafenib—thyroid cancer	0.00435	0.00435	CcSEcCtD
Neostigmine—Headache—Sorafenib—thyroid cancer	0.00433	0.00433	CcSEcCtD
Neostigmine—Pollakiuria—Epirubicin—thyroid cancer	0.00415	0.00415	CcSEcCtD
Neostigmine—Nausea—Sorafenib—thyroid cancer	0.0041	0.0041	CcSEcCtD
Neostigmine—Drowsiness—Epirubicin—thyroid cancer	0.004	0.004	CcSEcCtD
Neostigmine—Pollakiuria—Doxorubicin—thyroid cancer	0.00384	0.00384	CcSEcCtD
Neostigmine—Drowsiness—Doxorubicin—thyroid cancer	0.0037	0.0037	CcSEcCtD
Neostigmine—Bradycardia—Epirubicin—thyroid cancer	0.00366	0.00366	CcSEcCtD
Neostigmine—Urinary tract disorder—Epirubicin—thyroid cancer	0.00355	0.00355	CcSEcCtD
Neostigmine—Connective tissue disorder—Epirubicin—thyroid cancer	0.00353	0.00353	CcSEcCtD
Neostigmine—Urethral disorder—Epirubicin—thyroid cancer	0.00352	0.00352	CcSEcCtD
Neostigmine—Bradycardia—Doxorubicin—thyroid cancer	0.00339	0.00339	CcSEcCtD
Neostigmine—Flushing—Epirubicin—thyroid cancer	0.00334	0.00334	CcSEcCtD
Neostigmine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00328	0.00328	CcSEcCtD
Neostigmine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00327	0.00327	CcSEcCtD
Neostigmine—Urethral disorder—Doxorubicin—thyroid cancer	0.00326	0.00326	CcSEcCtD
Neostigmine—Mediastinal disorder—Epirubicin—thyroid cancer	0.00324	0.00324	CcSEcCtD
Neostigmine—Arrhythmia—Epirubicin—thyroid cancer	0.00321	0.00321	CcSEcCtD
Neostigmine—Mental disorder—Epirubicin—thyroid cancer	0.00315	0.00315	CcSEcCtD
Neostigmine—Flushing—Doxorubicin—thyroid cancer	0.00309	0.00309	CcSEcCtD
Neostigmine—Flatulence—Epirubicin—thyroid cancer	0.00308	0.00308	CcSEcCtD
Neostigmine—Muscle spasms—Epirubicin—thyroid cancer	0.00301	0.00301	CcSEcCtD
Neostigmine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.003	0.003	CcSEcCtD
Neostigmine—Arrhythmia—Doxorubicin—thyroid cancer	0.00297	0.00297	CcSEcCtD
Neostigmine—Mental disorder—Doxorubicin—thyroid cancer	0.00291	0.00291	CcSEcCtD
Neostigmine—Agitation—Epirubicin—thyroid cancer	0.00288	0.00288	CcSEcCtD
Neostigmine—Flatulence—Doxorubicin—thyroid cancer	0.00285	0.00285	CcSEcCtD
Neostigmine—Syncope—Epirubicin—thyroid cancer	0.00281	0.00281	CcSEcCtD
Neostigmine—Muscle spasms—Doxorubicin—thyroid cancer	0.00278	0.00278	CcSEcCtD
Neostigmine—Loss of consciousness—Epirubicin—thyroid cancer	0.00275	0.00275	CcSEcCtD
Neostigmine—Convulsion—Epirubicin—thyroid cancer	0.00271	0.00271	CcSEcCtD
Neostigmine—Arthralgia—Epirubicin—thyroid cancer	0.00266	0.00266	CcSEcCtD
Neostigmine—Agitation—Doxorubicin—thyroid cancer	0.00266	0.00266	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00265	0.00265	CcSEcCtD
Neostigmine—Dry mouth—Epirubicin—thyroid cancer	0.00261	0.00261	CcSEcCtD
Neostigmine—Syncope—Doxorubicin—thyroid cancer	0.0026	0.0026	CcSEcCtD
Neostigmine—Anaphylactic shock—Epirubicin—thyroid cancer	0.00255	0.00255	CcSEcCtD
Neostigmine—Loss of consciousness—Doxorubicin—thyroid cancer	0.00254	0.00254	CcSEcCtD
Neostigmine—Shock—Epirubicin—thyroid cancer	0.00251	0.00251	CcSEcCtD
Neostigmine—Convulsion—Doxorubicin—thyroid cancer	0.00251	0.00251	CcSEcCtD
Neostigmine—Nervous system disorder—Epirubicin—thyroid cancer	0.0025	0.0025	CcSEcCtD
Neostigmine—Tachycardia—Epirubicin—thyroid cancer	0.00249	0.00249	CcSEcCtD
Neostigmine—Skin disorder—Epirubicin—thyroid cancer	0.00248	0.00248	CcSEcCtD
Neostigmine—Hyperhidrosis—Epirubicin—thyroid cancer	0.00247	0.00247	CcSEcCtD
Neostigmine—Arthralgia—Doxorubicin—thyroid cancer	0.00246	0.00246	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00245	0.00245	CcSEcCtD
Neostigmine—Dry mouth—Doxorubicin—thyroid cancer	0.00241	0.00241	CcSEcCtD
Neostigmine—Hypotension—Epirubicin—thyroid cancer	0.00239	0.00239	CcSEcCtD
Neostigmine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00236	0.00236	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00233	0.00233	CcSEcCtD
Neostigmine—Shock—Doxorubicin—thyroid cancer	0.00232	0.00232	CcSEcCtD
Neostigmine—Nervous system disorder—Doxorubicin—thyroid cancer	0.00232	0.00232	CcSEcCtD
Neostigmine—Insomnia—Epirubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Neostigmine—Tachycardia—Doxorubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Neostigmine—Skin disorder—Doxorubicin—thyroid cancer	0.00229	0.00229	CcSEcCtD
Neostigmine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00228	0.00228	CcSEcCtD
Neostigmine—Dyspnoea—Epirubicin—thyroid cancer	0.00228	0.00228	CcSEcCtD
Neostigmine—Somnolence—Epirubicin—thyroid cancer	0.00227	0.00227	CcSEcCtD
Neostigmine—Hypotension—Doxorubicin—thyroid cancer	0.00221	0.00221	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.0022	0.0022	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00215	0.00215	CcSEcCtD
Neostigmine—Insomnia—Doxorubicin—thyroid cancer	0.00214	0.00214	CcSEcCtD
Neostigmine—Dyspnoea—Doxorubicin—thyroid cancer	0.00211	0.00211	CcSEcCtD
Neostigmine—Somnolence—Doxorubicin—thyroid cancer	0.0021	0.0021	CcSEcCtD
Neostigmine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00209	0.00209	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00204	0.00204	CcSEcCtD
Neostigmine—Urticaria—Epirubicin—thyroid cancer	0.00203	0.00203	CcSEcCtD
Neostigmine—Abdominal pain—Epirubicin—thyroid cancer	0.00202	0.00202	CcSEcCtD
Neostigmine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Neostigmine—Hypersensitivity—Epirubicin—thyroid cancer	0.00188	0.00188	CcSEcCtD
Neostigmine—Urticaria—Doxorubicin—thyroid cancer	0.00188	0.00188	CcSEcCtD
Neostigmine—Abdominal pain—Doxorubicin—thyroid cancer	0.00187	0.00187	CcSEcCtD
Neostigmine—Asthenia—Epirubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Neostigmine—Pruritus—Epirubicin—thyroid cancer	0.00181	0.00181	CcSEcCtD
Neostigmine—Diarrhoea—Epirubicin—thyroid cancer	0.00175	0.00175	CcSEcCtD
Neostigmine—Hypersensitivity—Doxorubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Neostigmine—Asthenia—Doxorubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Neostigmine—Dizziness—Epirubicin—thyroid cancer	0.00169	0.00169	CcSEcCtD
Neostigmine—Pruritus—Doxorubicin—thyroid cancer	0.00167	0.00167	CcSEcCtD
Neostigmine—Vomiting—Epirubicin—thyroid cancer	0.00162	0.00162	CcSEcCtD
Neostigmine—Diarrhoea—Doxorubicin—thyroid cancer	0.00162	0.00162	CcSEcCtD
Neostigmine—Rash—Epirubicin—thyroid cancer	0.00161	0.00161	CcSEcCtD
Neostigmine—Dermatitis—Epirubicin—thyroid cancer	0.00161	0.00161	CcSEcCtD
Neostigmine—Headache—Epirubicin—thyroid cancer	0.0016	0.0016	CcSEcCtD
Neostigmine—Dizziness—Doxorubicin—thyroid cancer	0.00156	0.00156	CcSEcCtD
Neostigmine—Nausea—Epirubicin—thyroid cancer	0.00152	0.00152	CcSEcCtD
Neostigmine—Vomiting—Doxorubicin—thyroid cancer	0.0015	0.0015	CcSEcCtD
Neostigmine—Rash—Doxorubicin—thyroid cancer	0.00149	0.00149	CcSEcCtD
Neostigmine—Dermatitis—Doxorubicin—thyroid cancer	0.00149	0.00149	CcSEcCtD
Neostigmine—Headache—Doxorubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Neostigmine—Nausea—Doxorubicin—thyroid cancer	0.0014	0.0014	CcSEcCtD
